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a b s t r a c t 
Introduction: The quick spread of SARS-CoV-2 led to the development of vaccines that are capable of 
reducing infection and the number of more severe COVID-19 cases. 
Aim: To assess COVID-19 prevalence among healthcare workers (HCWs) after vaccination against SARS- 
CoV-2. 
Methods: This was a cross-sectional study on the prevalence of COVID-19 diagnosis among 7523 HCWs 
vaccinated against SARS-CoV-2 with CoronaVac and ChAdOx1 nCoV-19 in a university hospital, in south- 
ern Brazil, between January 18 and March 18, 2021.The variables evaluated were: sex, age, work area, 
role, source of infection, previous diagnosis of COVID-19, date of vaccine administration, type of vaccine, 
and need for hospitalization. The statistical analysis used Poisson regression and Fisher’s exact test with 
SPSS software version 25, and a level of significance set at 5%. 
Results: 813 vaccinated HCWs showed symptoms suggestive of COVID-19, of whom 35.4% (288) had a 
detectable result after undergoing RT-PCR for SARS-CoV-2. There was a reduction of 62% in new cases 
of COVID-19 among HCWs in the institution 7 weeks after the start of vaccine rollout. Conclusion: Our 
data suggest that the vaccines used by the institution reduced the number of COVID-19 cases among 
healthcare workers, demonstrating the effectiveness of the vaccines. 
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 
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There is evidence that vaccines are able to reduce infection and 
he number of more severe cases of COVID-19 ( Bradley et al., 2021 ;
eehner et al., 2021 ; Daniel et al., 2021 ; Benenson et al., 2021 ).
he P1 variant of SARS-CoV-2 is refractory to multiple neutralizing 
onoclonal antibodies ( Wang et al., 2021 ). This may lead to anti- 
en alterations that impair vaccine protection, leading to a diagno- ∗ Corresponding author. 
E-mail addresses: stoniasso@hcpa.edu.br (S.d.C.C. Toniasso), 
scfernandes@hcpa.edu.br (F.S. Fernandes), djoveleviths@hcpa.edu.br (D. Jovele- 
iths), fffilho@hcpa.edu.br (F.F.D. Filho), atakahasi@hcpa.edu.br (A.Y. Taka- 
asi), cbaldin@hcpa.edu.br (C.P. Baldin), rompereira@hcpa.edu.br (R.M. Pereira), 









201-9712/© 2021 The Authors. Published by Elsevier Ltd on behalf of International Socie
icense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) is of infection in individuals in whom vaccine efficacy has been 
emonstrated ( Wang et al., 2021 ). 
ethods 
A cross-sectional study on the prevalence of COVID-19 diagnosis 
as conducted among 7523 healthcare workers (HCWs) vaccinated 
gainst SARS-CoV-2 with CoronaVac inactivated virus vaccine and 
hAdOx1 nCoV-19, using chimpanzee adenovirus as a viral vector 
or the expression of the SARS-CoV-2 spike protein, in a university 
ospital in southern Brazil. 4260 HCWs received CoronaVac (3676 
ith two doses and 584 with only one dose) and 3263 received 
ne dose of ChAdOx1 nCoV-19 between January 18 and March 18, 
021. In total, 813 health professionals with symptoms suggestive ty for Infectious Diseases. This is an open access article under the CC BY-NC-ND 
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Table 1 









N (%) N (%) 
525 (64.6) 288 (35.4) 
Work area Without patient assistance ∗ 68 (63.6) 39 (36.4) 1 
Non-COVID patient 
assistance ∗∗
316 (65.6) 166 (34.4) 0.94 0.690 0.71–1.25 
COVID patient assistance ∗∗∗ 141 (62.9) 83 (37.1) 1.02 0.915 0.75–1.38 
Role Other health professional ∗∗∗∗ 41 (78.8) 11 (21.2) 1 
Physician 61 (50.4) 60 (49.6) 2.34 < 0.05 1.35–4.08 
Nurse 261 (66.4) 132 (33.6) 1.59 0.095 0.92–2.73 
Care support 114 (68.3) 53 (31.7) 1.50 0.163 0.85–2.65 
Administration 48 (60) 32 (40) 1.89 < 0.05 1.05–3.41 
Origin of contact No identifiable contact 272 (69) 122 (31) 1 
External case 21 (63.6) 12 (36.4) 1.17 0.507 0.73–1.89 
Occupational suspicion 117 (65) 65 (35) 1.13 0.332 0.88–1.45 
Family 115 (55.8) 91 (44.2) 1.43 < 0.05 1.15–1.77 
COVID-19 confirmed in the 
past 
No 441 (61.5) 276 (38.5) 1 
Yes 84 (87.5) 12 (12.5) 0.32 < 0.05 0.19–0.56 
Vaccine Coronavac 306 (61.3) 193 (38.7) 1 
ChAdOx1 nCov-19 219 (69.7) 95 (30.3) 0.78 < 0.05 0.64–0.96 
∗ Without patient assistance: jobs that do not require contact with patients ( Baptista et al., 2021 ). 
∗∗ Non-COVID care: assistance to patients without a diagnosis of COVID-19. 
∗∗∗ COVID-19 care: assistance to patients diagnosed with COVID-19. 
































































f COVID-19 performed an RT-PCR (reverse transcriptase reaction 
ollowed by a polymerase chain reaction) test for SARS-CoV-2, and 
ad received at least one dose of the SARS-CoV-2 vaccine in the 
rst 9 weeks of the vaccination roll-out. 
The variables evaluated were: sex, age, work area, role, source 
f infection, previous diagnosis of COVID-19, date of vaccine ad- 
inistration, type of vaccine (ChAdOx1 nCoV-19 or CoronaVac), 
ate and result of the RT-PCR assay for SARS-CoV-2, number of 
rofessionals diagnosed with COVID-19 after vaccination, need for 
ospitalization, and admission to the intensive care unit (ICU). 
A prevalence ratio (PR) measure with 95% CI, estimated by Pois- 
on regression analysis with robust variance adjustment, was used 
o verify the factors and the strengths of the associations with the 
CR test result in the general sample, stratified by type of vaccine, 
hile Fisher’s exact test was used to assess the association of the 
accine with hospitalization and ICU outcomes among the COVID- 
9 patients. Analyses were performed using the SPSS software ver- 
ion 25, and the level of significance was set at 5%. 
The study was approved by the institutional Research Ethics 
ommittee (No. 308013240 0 0 05327), and financial support was 
rovided by the Research Incentive Fund (FIPE) of Hospital de Clin- 
cas de Porto Alegre. 
esults 
The 20–40 and 41–60 years age groups were represented sim- 
larly in our sample, accounting for 48% and 48.6%, respectively, 
f the total HCWs evaluated. 81.7% of the 813 evaluated HCWs 
ere females, and 35.4% (288) of those who underwent RT-PCR for 
ARS-CoV-2 showed a detectable result ( Table 1 ). 
The ChAdOx1 nCoV-19 vaccine decreased the prevalence of in- 
ection by 22% (PR: 0.78, 95% CI: 0.64-0.96). Regardless of the 
ype of vaccine, after the first dose, the prevalence of infection de- 
reased by 7% each week (PR: 0.93, 95% CI: 0.89-0.97). A previous 
iagnosis of COVID-19 reduced the prevalence of new infections by 
8% (PR: 0.32, 95% CI: 0.19–0.56). 
Among the 314 suspected cases who had received the ChAdOx1 
CoV-19 vaccine, a positive diagnosis for COVID-19 was observed 
n 30.3%. An important finding was that a previous diagnosis of 
OVID-19 at least 45 days earlier reduced the prevalence by 71% 284 PR: 0.29, 95% CI: 0.11–0.75) among these HCWs. When only HCWs 
ho had received one dose of ChAdOx1 nCoV-19 were considered, 
revalence was reduced by 10% each week after vaccination (PR: 
.90, 95% CI: 0.84–0.96) ( Table 2 ). 
Among the 399 suspected cases who had received the Coron- 
Vac vaccine, a positive diagnosis for COVID-19 was observed in 
8.7%. Physicians showed a 2.25-fold increased prevalence for a 
ositive diagnosis of COVID-19 compared with other HCWs with 
 higher education (PR: 2.25, 95% CI: 1.08–4.69). A previous diag- 
osis of COVID-19 reduced prevalence by 65% (PR: 0.35, 95% CI: 
.18–0.67) ( Table 2 ). 
A hospitalization outcome was observed in 14 of the 288 
OVID-19 patients. However, no cases with positive RT-PCR died 
fter the administration of both vaccines during the period under 
tudy. 
iscussion 
Our data suggest that, after the first dose, the prevalence of 
nfection decreased every week, regardless of the type of vac- 
ine. Within our population, ChAdOx1 nCoV-19 seemed to provide 
etter protection in relation to COVID-19, and further studies are 
eeded to identify the cause of this difference. 
The higher prevalence among physicians, identified in our pop- 
lation, may be associated with the prevalence of double work- 
ng hours, with different levels of exposure and protection against 
OVID-19. 
The different levels of protection against COVID-19, such as the 
se of personal protective equipment, may be associated with a 
ower prevalence of positive cases in the occupational environment 
hen compared with other environments. However, more studies 
re needed in this area. 
The presence of a previous diagnosis of COVID-19 was a protec- 
ive factor against new SARS-CoV-2 infections. In agreement with 
ur data, studies carried out in Denmark and Qatar indicated that 
he presence of a previous diagnosis of COVID-19 infection can pro- 
ide protection against a new infection of up to 78.8% and 95%, 
espectively ( Hansen et al., 2021 ; Abu-Raddad et al., 2021 ). 
Our data are also in agreement with those of a study conducted 
n Israel in evidencing a decline in cases of COVID-19 and in se- 
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Table 2 
Factors associated with the diagnosis of COVID-19 — vaccinated with CoronaVac and ChAdOx1 nCov-19 













N (%) N (%) N (%) N (%) 
219 (70) 95 (30) 306 (61) 193 (39) 
Work area Without 
patient 
assistance ∗




23 (63.9) 13 (36.1) 0.84 0.430 (0.54–1.9) 153 (60.2) 70 (37.2) 0.96 0.871 0.72–1.48 
COVID patient 
assistance ∗∗∗
163 (71.5) 65 (28.5) 1.06 0.839 (0.59–1.3) 118 (62.8) 101 (39.8) 1.03 0.852 0.66–1.41 
Role Other health 
professional ∗∗∗∗
20 (80) 5 (20) 1 21 (77.8) 6 (22.2) 1 
Physician 15 (51.6) 15 (48.4) 2.42 < 0.05 (1.02–5.74) 45 (50) 45 (50) 2.25 < 0.05 1.08–4.69 
Nurse 101 (73.2) 37 (26.8) 1.34 0.489 (0.58–3.08) 160 (62.7) 95 (37.3) 1.68 0.162 0.81–3.46 
Care support 61 (71.8) 24 (28.2) 1.41 0.429 (0.60–3.32) 53 (64.6) 29 (35.4) 1.59 0.233 0.74–3.42 
Administration 21 (60) 14 (40) 2.00 0.124 (0.83–4.84) 27 (60) 18 (40) 1.8 0.145 0.82–3.97 
Origin of contact No identifiable 
contact 
123 (45) 41 (25) 1 149 (64.8) 81 (35.2) 1 
External case 7 (70) 3 (30) 1.2 0.716 (0.45–3.21) 14 (60.9) 9 (39.1) 1.11 0.702 0.65–1.9 
Occupational 
suspicion 
40 (74.01) 14 (25.9) 1.04 0.892 (0.61–1.75) 77 (61.1) 49 (38.9) 1.10 0.488 0.83–1.46 
Family 49 (57) 37 (43) 1.72 < 0.05 (1.2–2.47) 66 (55) 54 (45) 1.28 0.069 0.98–1.66 
COVID-19 confirmed in 
the past 
No 182 (66.7) 91 (33.3) 1 259 (58.3) 185 (41.7) 1 
Yes 37 (90.02) 4 (9.8) 0.29 < 0.05 (0.11–0.75) 47 (85.5) 8 (14.5) 0.35 < 0.05 0.18–0.67 
∗ Without patient assistance: jobs that do not require contact with patients. 
∗∗ Non-COVID patient assistance: assistance to patients without a diagnosis of COVID-19. 
∗∗∗ COVID patient assistance: assistance to patients diagnosed with COVID-19. 





















W  ere forms of the disease following the start of vaccine rollout 
 Rossman et al., 2021 ). 
onclusion 
Our data suggest that the vaccines used by the institution re- 
uced the number of COVID-19 cases among HCWs, and protected 
gainst severe forms of the disease. 
Analysis of the cases with SARS-CoV-2-positive RT-PCR showed 
hat there was a possibility of infection after the administration 
f a COVID-19 vaccine. Further studies are needed to confirm this 
n the medium and long term, taking into account the types of 
irus in circulation in the country, and also the types of vaccine 
dministered. 
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